N@N

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Somanetics Corporation

^{Published on 2010-06-23 07:51:35 - Market Wire}
 

NEW YORK--([ BUSINESS WIRE ])--Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Somanetics Corporation (NASDAQ: SMTS) (referred to as "Somanetics" or the aCompanya) by Covidien plc (NYSE: COV) (referred to as "Covidien") for $25.00 per share in cash, for a total of $250 million, net of cash acquired.

The transaction, which will take the form of an all-cash tender offer by a wholly-owned subsidiary of Covidien, followed by a second-step merger, is subject to closing conditions, including receipt of certain regulatory approvals, and is expected to be completed by July 31, 2010. The Boards of Directors of both companies have unanimously approved the transaction.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Companya™s shareholders.

If you are a holder of Somanetics stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.

If you are a shareholder of Somanetics and would like more information about our investigation, please contact Peter D. Bull, Esq. by telephone at (866) 313-6222 or by sending an e-mail including your contact information to: [ counsel@nyclasslaw.com ]. All e-mail correspondence should make reference to Somanetics.

Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at [ www.nyclasslaw.com ].

ATTORNEY ADVERTISING. © 2010 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41^st Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect to any future matter.